Data / Drug companies / Remedyrepack Inc.
Remedyrepack Inc.: 1,541 products in the FDA NDC directory, labeler code 70518
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Remedyrepack Inc. (labeler code 70518) lists 1,541 products in the FDA National Drug Code Directory, covering 366 finished drugs by generic name. By type: 1,536 prescription drugs, 5 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 4, 2026.
The request: Watch Remedyrepack Inc. (FDA labeler code 70518): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70518
- Products in commercial distribution
- 1,541
- Packages
- 2,698
- Finished drugs by generic name
- 366
- Prescription products
- 1,536
- Over the counter products
- 5
- Controlled substance products
- Schedule III 16, Schedule IV 58, Schedule V 31
- Started marketing in the last 12 months
- 265
- Products with a marketing end date set
- 17
- Earliest marketing start
- November 23, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 1,457 | 94.5% |
| Authorized generics (NDA) | 31 | 2% |
| New drug applications (NDA) | 29 | 1.9% |
| Other unapproved drugs | 15 | 1% |
| Over the counter monograph drugs | 5 | 0.3% |
| Biologics (BLA) | 4 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 1,536 | 99.7% |
| Over the counter drugs | 5 | 0.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 580 | 37.6% |
| Tablet, film coated | 370 | 24% |
| Capsule | 218 | 14.1% |
| Tablet, extended release | 76 | 4.9% |
| Injection, solution | 34 | 2.2% |
| Tablet, film coated, extended release | 30 | 1.9% |
| Injection | 29 | 1.9% |
| Capsule, extended release | 27 | 1.8% |
| Tablet, coated | 25 | 1.6% |
| Tablet, delayed release | 21 | 1.4% |
| Solution | 20 | 1.3% |
| Cream | 17 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dexlansoprazole delayed release | 70518-4791 | Capsule, delayed release | Generic drugs (ANDA) | November 4, 2026 |
| Tramadol Hydrochloride | 70518-4790 | Tablet | Generic drugs (ANDA) | November 3, 2026 |
| Acetaminophen | 70518-4787 | Tablet | Over the counter monograph drugs | October 28, 2026 |
| Ibuprofen | 70518-4786 | Tablet, film coated | Generic drugs (ANDA) | October 28, 2026 |
| Naloxone hydrochloride | 70518-4785 | Injection, solution | Generic drugs (ANDA) | October 28, 2026 |
| Ibuprofen | 70518-4784 | Tablet, film coated | Generic drugs (ANDA) | October 28, 2026 |
| Acetaminophen | 70518-4783 | Tablet | Over the counter monograph drugs | October 25, 2026 |
| Acetaminophen | 70518-4782 | Tablet, film coated | Over the counter monograph drugs | October 25, 2026 |
| Metformin Hydrochloride | 70518-4781 | Tablet, film coated | Generic drugs (ANDA) | October 25, 2026 |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | 70518-4780 | Tablet, film coated | Generic drugs (ANDA) | October 25, 2026 |
| Venlafaxine | 70518-4779 | Tablet | Generic drugs (ANDA) | October 19, 2026 |
| Pregabalin | 70518-4778 | Capsule | Generic drugs (ANDA) | October 19, 2026 |
| Medroxyprogesterone Acetate | 70518-4777 | Tablet | Generic drugs (ANDA) | October 17, 2026 |
| Esomeprazole Magnesium | 70518-4776 | Capsule, delayed release | Generic drugs (ANDA) | October 16, 2026 |
| Calcitriol | 70518-4775 | Capsule, liquid filled | Generic drugs (ANDA) | October 15, 2026 |
| Glimepiride | 70518-4774 | Tablet | Generic drugs (ANDA) | October 15, 2026 |
| Losartan potassium | 70518-4773 | Tablet, film coated | Generic drugs (ANDA) | October 15, 2026 |
| Regular Strength Enteric coated aspirin | 70518-4772 | Tablet, coated | Over the counter monograph drugs | October 14, 2026 |
| Adult Low Dose Enteric Coated Aspirin | 70518-4771 | Tablet, coated | Over the counter monograph drugs | October 13, 2026 |
| Oseltamivir phosphate | 70518-4770 | Capsule | Generic drugs (ANDA) | October 9, 2026 |
| Quetiapine Extended Release | 70518-4769 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 8, 2026 |
| Trospium Chloride | 70518-4768 | Tablet, film coated | Generic drugs (ANDA) | October 8, 2026 |
| Metronidazole | 70518-4767 | Tablet, film coated | Generic drugs (ANDA) | October 5, 2026 |
| Nortriptyline Hydrochloride | 70518-4766 | Capsule | Generic drugs (ANDA) | September 25, 2026 |
| Diphenhydramine | 70518-4765 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.